CSI Market
Sign In | Register

Bellicum Pharmaceuticals Inc (BLCM) Annual Income Statement

Annual · GAAP · USD millions
Access BLCM quarterly income statements →
Income statement data covering Bellicum Pharmaceuticals Inc–Dec 31 2018 offers a view into how Dec 31 2022's operating results have moved alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2022)
2022 		(Dec 31 2021) (Dec 31 2020) (Dec 31 2019) (Dec 31 2018)
Revenues
Revenue From Contract With Customer Excluding Assessed Tax1.50
Total Revenue1.50
Costs & Expenses
Cost of Goods and Services Sold0.00
Gross Profit1.50
Selling, Administration, Marketing5.72
Research and Development Expense22.76
Tangible Asset Impairment Charges0.00
Other Operating Expense / -Income0.00
Total operating costs including COS28.48
Operating income / -loss-26.98
Interest Expense0.05
Net Interest Expense / -Income0.05
Extinguishment of Debt0.00
Other loss / -income-27.02
Total costs & expenses1.50
Income & Taxes
Income / -loss before income taxes0.00
Income taxes expenses / -benefit0.00
Income after income taxes0.00
Income / -loss from continuing operations0.00
Other-24.97
Net income / -loss0.00
Income / -loss to shareholder-24.97
EBIT0.04
EBITD0.05
EBITDA0.05
Earnings Per Share
Basic EPS (excl. extra items)-0.81
Basic Net EPS-0.81
Basic shares outstanding (Mill. of Units)30.83
Diluted Net EPS-0.81
Diluted average shares (Mill. of Units)30.83
4 historic quarters locked

Sign in to unlock the full Bellicum Pharmaceuticals Inc income statement history.

Sign In Create Free Account

About BLCM Annual Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-K filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-K filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.